MyelinWatch EL
← Back to updates
Emerging treatmentsMyelin repair
Results from peopleCompletedBiological signal in biomarkers, not proof of clinical benefit

Results from people

MSC-NP study finds CSF biomarker changes in two progressive MS cohorts

Research group
Tisch Multiple Sclerosis Research Center of New York · United States
Funder
National Multiple Sclerosis Society and the Damial Foundation
Researcher
Violaine K. Harris
Research event/source date
Published by MyelinWatch
Last substantive MyelinWatch update

What happened

A published analysis examined cerebrospinal-fluid samples from two groups of people with secondary or primary progressive MS: 50 participants in a Phase 2 study and 43 in an expanded-access programme. After repeated intrathecal autologous MSC-NP treatment, CCL2, MMP9, SCF and CHIT1 changed in cerebrospinal fluid. NfL and GFAP did not show the same pattern of change.

What this means for people with MS

These findings may help measure biological response and guide future study design. They do not show remyelination, improvement in symptoms or disability, or an established benefit to patients.

What kind of evidence exists?
Peer-reviewed biomarker analysis from two groups of people
How reliable is this source?
Strong for the biomarker analysis • peer-reviewed original paper with reported study identifiers

Related study or programme: MSC-NP / Tisch →

Source: Stem Cells Translational Medicine / Tisch Multiple Sclerosis Research Center of New York — peer-reviewed primary article ↗

Related substantive developments

Myelin repair
Laboratory or animal researchLaboratory or animal programmePromising early finding

Laboratory and animal research

Blocking fibronectin restored remyelination in experimental models

A PNAS study found that a protein called fibronectin can build up in areas where myelin has been lost. This may trap immature cells that could otherwise become myelin-making cells. Blocking fibronectin improved myelin repair and symptoms in two animal models.

What this means for people with MS

This points to an interesting new biological target, but the approach has not been tested in people and there is no approved medicine based on it.

Read the update →Source: PubMed / PNAS — peer-reviewed paper ↗
Emerging treatmentsMyelin repair
Preparing for first human studiesAnnounced or plannedNo evidence of benefit in people yet

Preparing for human testing

Low-dose theophylline patch receives funding to prepare for its first study in people

Research group: Johannes Gutenberg University Mainz · Germany

Claire Jacob's team at Johannes Gutenberg University Mainz announced €1.1 million to improve the skin patch, manufacture it to pharmaceutical standards and prepare a first safety study in healthy volunteers.

What this means for people with MS

The funding brings the patch closer to human testing, but the first study is not yet publicly registered and there is no evidence of benefit in people with MS.

Read the update →Source: Johannes Gutenberg University Mainz — official university research update ↗
Emerging treatmentsMyelin repair
Registered study in peopleOngoing, but not accepting participantsNo evidence of benefit in people yet

Phase 3 study that can add or remove treatments

OCTOPUS: the first review of metformin and alpha-lipoic acid is planned for September 2026

Research group: MRC Clinical Trials Unit at UCL · United Kingdom

The first OCTOPUS review in progressive MS will assess metformin and alpha-lipoic acid. It will look at brain shrinkage on MRI, disability, walking speed and hand function.

What this means for people with MS

This is one of the nearest important milestones in progressive MS. The review may decide which treatment groups continue, but it is not the final Phase 3 result.

Read the update →Source: OCTOPUS / MRC Clinical Trials Unit at UCL — official trial update ↗